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Abstract 
Introduction:  Laeverin is a placenta-specific protein that is normally expressed in the plasma 
membrane of human trophoblasts. In previous studies, we showed higher expression levels of 
laeverin gene in preeclamptic compared to normal placentas and found that laeverin protein was 
ectopically expressed in the cytoplasma of the preeclamptic placentas. Our objective was to 
investigate laeverin protein expression in normal and preeclamptic placentas combining 
immunohistochemistry and immunofluorescence. Material and methods: Tissue microarray analysis 
of 72 placentas, obtained from 33 preeclamptic and 39 uncomplicated pregnancies was performed. 
Laeverin was labelled with a specific antibody for immunohistochemistry and immunofluorescence 
studies. Results: Immunohistochemistry showed that laeverin was expressed in 
syncytiotrophoblasts, cytotrophoblasts and extravillous trophoblasts in all placentas examined. In 
preeclamptic placentas (n=33) compared to normal placentas (n=39), laeverin was expressed in the 
cell membrane in 21 (64%) vs 21 (54%) of samples (p=0.726), in the cytoplasm in 3 (9%) vs 2 (5%) of 
samples (p=0.795) and in both the cytoplasm and membrane in 9 (27%)  vs 16 (41%) of samples 
(p=0.0522). All placental samples that showed cytoplasmic expression of laeverin were obtained 
from women delivered before 34 weeks of gestation (early-onset preeclampsia). Further, 
immunofluorescence studies showed laeverin expression in the cytoplasm of six preeclamptic (three 
early-onset and three late-onset) and one normal placenta but did not reveal any simultaneous cell 
membrane and cytoplasmic expression of laeverin. Conclusion: Laeverin is expressed in all 
trophoblast cell types of normal and preeclamptic placentas. Expression pattern of laeverin in 
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Key message 




Preeclampsia is a pregnancy specific syndrome associated with defective placentation (1). 
The placenta is a heterogeneous organ containing several types of trophoblastic cells, mainly 
comprising  cytotrophoblasts - that are the progenitor cells of the syncytiotrophoblasts - and 
extravillous trophoblasts (EVT) which invade the maternal endometrium to establish the feto-
maternal circulation (2). EVTs are also found in the chorionic plate, the smooth chorion (chorion 
leave), the cell columns, the basal plate and in the placental septa (3). The syncytiotrophoblasts form 
the outer lining of the chorionic villi, which are the functional units of the placenta and create the 
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syncytiotrophoblast derived extracellular vesicles (7, 8) are shed into the maternal circulation during 
normal pregnancy and in pregnancy related diseases. This phenomenon is thought to be especially 
pronounced in preeclampsia (9).  
  Laeverin, also called Aminopeptidase Q, is a cell-surface marker of human EVT (10) and 
might play a regulatory role in EVT migration (11). We showed previously on individual placentas 
obtained from women with severe preeclampsia that laeverin might be ectopically expressed in the 
cytoplasma of villous trophoblasts (12). 
 Tissue microarray (TMA) is based on assembling many tissue samples on a single slide 
allowing simultaneous microscopic histological examination (13). TMA is a high-throughput and 
cheap method investigating the expression of proteins, RNA or DNA using immunohistochemistry 
(IHC), immunofluorescence (IF) and fluorescence/chromogenic in situ hybridization methods (ISH). 
The method was initially developed and designed for molecular profiling of tumor specimens (14), 
but may also be used for other purposes. Indeed recent studies have shown that TMA is feasible for 
placental investigation (15, 16). 
In this study we used a series of placental tissue samples obtained from clinically well-
characterized patients with severe preeclampsia and healthy controls to construct TMA blocks. We 
hypothesized that laeverin protein is differently expressed in placentas obtained from healthy and 
preeclamptic pregnancies. Our objective was to investigate laeverin protein expression in a series of 
normal and preeclamptic placentas combining IHC and IF methods. 
 
Material and methods  
TMA slides were prepared from 77 placental tissue samples obtained from 36 women with 
severe preeclampsia and 41 women with uncomplicated pregnancies. Severe preeclampsia was 
defined as blood pressure ≥160/110mmHg and proteinuria ≥300mg/24 hour urine or ≥2+ in spot 
urine after 20 weeks of gestation in previously normotensive women according to International 
Society for the study of Hypertension in Pregnancy (ISSHP) criteria (17).  All the preeclamptic women 
included in our study received antihypertensive therapy. Doppler ultrasonography was performed 
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Placentas were collected immediately after delivery and submerged in formaldehyde (4%) 
solution. Hematoxylin/eosin staining (18) was performed on individual formalin fixed paraffin 
embedded (FFPE) placental tissue slides (4 µm thick tissue sections) of  all participants according to 
standard protocols.  
The area of interest, consisting of macroscopically normal villous parenchyma, was localized 
by inspection of hematoxylin/eosin stained slides. Separate tissue cores (0.6 mm in diameter) of 
each individual paraffin block were punched out from primary blocks and mounted in a Manual 
Tissue Arrayer MTA-1 (Beecher Instruments, Sun Prairie, WI, USA) (Figure 1). Duplicates of each 
donor block to paraffin recipient blocks were used in each array. In addition, technical 
quadruplicates were performed in 4 samples. Two different array blocks (A and B) were used in the 
experiments; with different quantity of negative controls (normal liver samples; 4 in A- and 2 in B-
block).  Each TMA-block was then incubated at 37°C for 10 minutes to make a homogeneous block. 
These blocks were then cut (4 µm thick tissue sections) and mounted on SuperfrostTM Plus glass 
slides (Thermo Fischer Scientific, Boston, MA, USA) according to standard procedures. TMA-sections 
on slides were mounted in paraffin in order to protect epitopes of the proteins and stored at 4°C 
until staining.  
 The following antibodies were used: Laeverin (rabbit polyclonal anti-Laeverin ab185345; 
AbCam, Cambridge, UK) and cytokeratin 7 (CK7) (rabbit monoclonal anti-CK7, SP52, code 
05986818001; Roche, Tucson, USA) antibodies were used for IHC and IF on the TMA-slides. 
IHC studies were performed on two separate tissue sections of the individual A- and B-TMA 
FFPE blocks with antibodies against laeverin and CK7 using the Ventana Discovery Ultra research 
Instrument (Ventana Medical Systems, Inc., Roche, Tucson, USA). Separate labeling protocols for 
laeverin and CK7 were used. Slides were incubated at 56-60°C for minimum 4 hours to dissolve most 
of the paraffin before IHC-staining and analysis. 
The TMA slide was deparaffinized in EZ-PrepTM using heat at 68°C in three different cycles of 
12 min each. Antigen unmasking and epitope-retrieval was done using heat treatment at 95°C in 
EDTA-buffer (pH 8.0-8.5) for repeated steps of 4 minutes, in total 32 minutes. Inhibitor CM was 
added and incubated for 12 minutes. Primary anti-laeverin antibody (1:50 dilution in PBS; final 
concentration 6 ng/μl) or anti-CK7 antibody (pre-diluted) and incubated at 36°C for 60 minutes for 
laeverin and 44 minutes for CK7.  OmniMap (OMAP)-anti rabbit multimer horse raddish peroxidase 
(HRP) (code 5269679001; Roche, Tucson, USA) was added and incubated for 16 minutes for laeverin 
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Discovery anti-HQ HRP both 8 minutes to give multimere Tyramide Signal Amplification (TSA™). 
ChromoMap 3,3′-Diaminobenzidine (DAB) and H2O2 was used for the last step of detection. Ultra 
liquid coverslip (oil) was used to prevent evaporation in each step. Details of the protocols are 
presented in Supporting Information Appendices S1 and S2.  
Pictures were taken on an inverted light microscope (Leica DMI6000B; Leica microsystems, 
Wetzlar, Germany) with LAS v4.4 imaging software (Leica microsystems, Wetzlar, Germany). 
IF studies were performed on two separate sections of the individual A- and B-TMA FFPE 
blocks with antibodies against laeverin and CK7 using the Ventana Discovery Ultra research 
Instrument (Ventana Medical Systems, Inc., Roche, Tucson, USA). Slides were incubated at 56-60°C 
for minimum 4 hours to dissolve most of the paraffin before IF-staining and analysis. 
The TMA-slide was deparaffinized in EZ-PrepTM using heat at 68°C in three different cycles of 
12 min each. Antigen unmasking and epitope-retrieval was done using heat treatment at 95°C in 
EDTA-buffer (pH 8.0-8.5) for repeated steps of 4 minutes, in total 40 minutes. Inhibitor CM was 
added and incubated for 12 minutes. Antibody block was added and incubated for 16 minutes at 
37°C. Primary added rabbit anti-laeverin antibody was manually added (ab185345; AbCam, 
Cambridge, UK)(1:50 dilution in PBS; final concentration 6 ng/μl) and the slide was then incubated at 
36°C for 60 minutes. Multimer HRP-blocking was added and incubated for 16 minutes before  
OmniMap (OMAP)-anti rabbit multimer HRP (code 5269679001; Roche, Tucson, USA) was added and 
incubated for 20 minutes. Rhodamine labelled secondary antibody (Discovery Rhodamine kit, code 
07259883001; Roche, Tucson, USA) was added and incubated for 1 hour and 20 minutes. The 
antibodies were then denaturated using heat at 90°C for 8 minutes. Antibody block was added and 
incubated for 16 minutes for 37°C. Primary rabbit anti-CK7 antibody (Rabbit monoclonal (SP52), 
code 05986818001; Roche, Tucson, USA) was manually added and the slide was then incubated at 
36°C for 60 minutes. Multimer HRP-blocking was added and incubated for 16 minutes before  
OmniMap (OMAP)-anti rabbit multimer HRP (code 5269679001; Roche, Tucson, USA) was added and 
incubated for 20 minutes. FITC labelled secondary antibody (Discovery FITC kit, code 07259212001; 
Roche, Tucson, USA) was added to the slide and incubated for 32 minutes before the slide was 
cleaned. Manual washing in Elix water (Elix Advantage Water Purification System, Massachusetts, 
USA) and colorless soap (Pantastic Clean, ECOLAB Etterstad, Norge) was performed to get rid of oil. 
Slides were then air dried and counterstained with DAPI (4’,6-diamidino-2-phenylindole) II (Abbott 
Molecular Inc., Des Plaines, IL 60018, USA). Details of the protocol is presented in Supporting 
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Imaging analysis was performed in a Nicon Eclipse E800 fluorescence microscope (Nikon 
Instruments Inc., Melville, NY, USA). Images were obtained using a CytoVision (Applied Imaging, San 
Jose, CA, USA) digital system equipped with a CCD camera (Cohu Inc., San Diego, USA). 
Pictures from the most intensively laeverin and CK7 stained areas of all cores were taken and 
scored independently by two scientists [one pathologist (CN) and one cytogeneticist (MN)], before 
inter-observer correlation was done. IF studies were performed by an experienced cytogeneticist 
(MN). The following scoring criteria for laeverin protein expression were used: 
• Membrane staining  
• Cytoplasmic staining  
• Membrane and cytoplasmic staining 
• Negative; not expressed  
• Co-localization of laeverin with CK7 (only for IF studies)  
 
Statistical analyses 
Differences between groups were tested using Student’s t-test for parametric variables and 
Mann-Whitney U test for non-parametric variables as appropriate. A p-value of <0.05 was 
considered significant. Kappa value (19, 20) for inter-rater reliability was calculated for the IHC 
studies. The kappa value was based on analysis of 35 placentas obtained from uncomplicated 
pregnancies and 28 placentas from women with severe preeclampsia. The two raters used three 
criteria for rating: Laeverin protein localization in membrane of trophoblast cells, in cytoplasm of 
trophoblast cells or expression in both membrane and cytoplasm of trophoblasts.  Data were 
analyzed with IBM SPSS Statistics 23 software (SPSS Inc, Chicago, IL).  
 
Ethical approval 
The study was approved by the Regional Committee for Medical and Health Research Ethics-
North Norway (REK Nord ref. number 2010/2058-4) and informed written consent was obtained 
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Results  
The baseline demographic characteristics and clinical phenotype of the study population are 
shown in Table 1. There were significant differences in mean arterial pressure, uterine artery 
pulsatility index, uterine artery pulsatility index, umbilical artery pulsatility index, gestational age at 
delivery, cesarean section rate, neonatal birth weight, placental weight, 5 min Apgar score and 
venous cord blood pH between preeclamptic and uncomplicated pregnancies.  
Tissue microarray slides were of high quality and the histological details were clear in both 
IHC (Figure 2) and IF studies (Figure 3) for each core. Two scientists scored the IHC TMA slides blindly 
to evaluate the technical performance of IHC studies. We found 5.6% discordance (in 4 of 72 
duplicates) in scoring. The inter-rater reliability (Cohen’s kappa) was 0.890 (SE 0.047). 
 Laeverin was expressed in syncytiotrophoblasts, cytotrophoblasts and EVT in all placentas. 
Expression of laeverin in cell membranes, cytoplasm or both in preeclamptic compared to normal 
placentas is presented in Table 2. Laeverin was not expressed in stromal cells. The differences 
regarding the subcellular localization of laeverin protein were not statistically significant between 
healthy and preeclamptic placentas in the IHC studies (Table 2A). However, all placentas with only 
cytoplasmic expression of laeverin had early onset disease i.e. required delivery before 34 weeks of 
gestation (Table 2B). Laeverin was also expressed in syncytial knots; more pronounced in 
preeclamptic compared to normal placentas (Figure 2D). 
IF studies were performed to validate the IHC results, using co-labeling of CK7 specific 
antibody to identify trophoblast cell populations (21, 22) and laeverin specific antibody.  
Immunofluorescence studies did not reveal any membrane and cytoplasmic expression of 
laeverin protein simultaneously. Laeverin was expressed in the cytoplasm of 6 preeclamptic 
placentas (3 early- and 3 late-onset preeclampsia) and in only one normal placenta.  
 
Discussion 
In this study we investigated the expression of laeverin protein in a series of normal and 
preeclamptic placentas. We found laeverin to be expressed in syncytiotrophoblasts, 
cytotrophoblasts and EVT in all placentas. In a previous study (12) we found that laeverin might be 
ectopically expressed in the cytoplasm and microvesicles in cytotrophoblasts of preeclamptic 
placentas, rather than in the cell membrane. Therefore, we hypothesized that it might be possible to 
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expression. However, in the present study we discovered that some healthy placentas also have 
cytoplasmic laeverin expression, indicating that laeverin cannot be used as a specific diagnostic 
biomarker of preeclampsia in pathological specimens using IHC. However, in IHC, there were more 
preeclamptic placentas with only cytoplasmic expression of laeverin (9%) compared to normal 
placentas (5%), indicating that laeverin might play a role in the molecular pathophysiology of 
preeclampsia. The differences between the groups were not statistically significant, but our study 
was underpowered to demonstrate significant differences regarding dissimilar subcellular 
localization of laeverin between healthy and preeclamptic placentas. Another possible reason for the 
discordance with our previous study could be the use of different antibodies; one antibody binds to 
epitopes located to amino acid position 960-990 on the outer surface of the protein, including the 
COOH-end of laeverin and was house-made by rabbit immunization (12). On the other hand, the 
antibody used in this study is a commercial (AbCam) recombinant fragment of human laeverin, 
which is longer, targeting amino acids 818-905 of the laeverin protein. Interestingly all of the 
preeclamptic placentas expressing laeverin in the cytoplasm were delivered before 34 weeks 
gestation. This is in line with our previous finding of higher laeverin expression in the maternal 
circulation in early pregnancy (23), and laeverin’s role in migration and invasion capacities of first 
trimester trophoblasts (24).    
The IF co-localization studies of laeverin and CK-7 showed either membrane or cytoplasmic 
expression; no simultaneous membrane and cytoplasmic expression of laeverin was detected (Figure 
2). The advantage of using the two markers together in the same IF study, is that cytoplasma 
expression could easily be detected (as a yellow signal), where both CK7 and laeverin are co-
expressed. Moreover, the company producing the antibody provided pictures of healthy human 
placenta showing membrane expression. Further, the presence of a transmembrane motif of 
laeverin protein further argues for a membrane-only expression in normal placenta (10). 
We found that only a subset of preeclamptic placentas with early onset disease showed 
intracytoplasmatic expression of laeverin, together with a placenta obtained from a woman with 
uncomplicated pregnancy, but with histologic signs of chorioamnionitis, which was not included in 
the analysis (data not shown). This is an interesting finding indicating that laeverin might be involved 
and/or disarranged in the inflammatory process, which is excessive in preeclampsia (23). Moreover, 
the results of the present study challenge the knowledge that laeverin is a membrane bound 
aminopeptidase, indicating other possible enzymatic functions of this protein during normal 
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placenta (24). We did not have sufficient samples to answer whether all preeclamptic placentas 
delivered at term lack laeverin expression intracytoplasmatically. 
The limitations of our study are mainly related to pre-TMA sample preparation, i.e. size of 
tissue used in fixation, different exposure time in air before fixation and different exposure time of 
the individual placentas to formalin. Moreover, the placenta is a relatively heterogeneous organ 
containing different cell types. Therefore, the cores for the construction of the TMA should be 
carefully chosen to get a representative area of interest for investigation. A TMA has the advantage 
of including many samples lowering the costs are providing similar experimental conditions for all 
samples. However, the scoring procedure demands experienced personnel and provides a large 
amount of data to handle. Nevertheless, we found an inter-rater reliability (Kappa) value of 0.890 
(standard error 0.047) suggesting a strong level of agreement between the raters (19). Another 
limitation of our study is that we did not include cases of mild preeclampsia and we were therefore 
not able to perform a subgroup analysis for this population. Furthermore, in the TMA, there was a 
mixture of placentas delivered vaginally and by emergency or elective cesarean sections. In a 
previous study (25) we compared gene expression profile of placentas delivered vaginally following 
normal labor with placentas delivered by elective cesarean section before the onset of labor, and 
found that global placental gene expression profile is not affected by labor. We specifically 
measured the expression profile of laeverin in these placentas (data not shown) and we did not find 
any differences. Therefore, we do not have any indication that the expression of laeverin protein 
might be influenced by mode of delivery, but possible influence of laeverin expression by induced or 
prolonged labor cannot be excluded. 
  Regarding the performance of the techniques used, IHC of single samples was proven to be a 
good tool for initial screening of placenta tissue, while antibody-labeled TMA sections from many 
placentas was shown to be a versatile and cheap method for screening a series of samples 
simultaneously. Moreover, placental TMA IHC and IF seem to complement each other. In particular, 
IHC gives better morphological overview and easy recognition of histological features characterizing 
the preeclamptic placenta, such as syncytical knots. For example, we found by IHC that laeverin 
appears to be polarized to the plasma membrane facing the intervillous space. On the other hand, IF 
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  Quantitative measurements of laeverin protein expression would have been preferable to do, 
especially since we noticed differences in expression patterns of laeverin regarding the intensity of 
membrane staining between normal and preeclamptic placentas (Figure 2A compared to Figure 2C). 
However, standard IHC and IF are not suitable for quantitative measurements, whereas automated 
quantitative IF or mass spectrometry may be used for this purpose.  
  In conclusion, we demonstrated laeverin expression in EVT, villous cytotrophoblasts and 
syncytiotrophoblasts in all placentas. Laeverin is expressed both in the cell membrane and in the 
cytoplasm in normal as well as in preterm delivered preeclamptic placentas, indicating possible 
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Supporting Information legends 
 
Appendix S1: Ventana Discovery automatic immunohistochemistry protocol for laeverin labelling. 
(Ventana Discovery automatic IHC RUO DISCOVERY Universal (v0.00.0265) Protocol name 561 
Laeverin 185345 AMP.) 
 
Appendix S2: Ventana Discovery automatic immunohistochemistry protocol for CK7 labelling. 
(Ventana Discovery automatic IHC RUO DISCOVERY Universal (v0.00.0265) Protocol name 483 R 
CK7). 
 
Appendix S3: Ventana Discovery automatic immunofluorescence protocol for co-labelling of Laeverin 
and CK7. (Ventana Discovery automatic immunofluorescence RUO DISCOVERY Universal 
(v0.00.0265) Protocol name 586 Laev-CK7 RHOD-FITC 120). 
 
 
Table  and Figure Legends  
 
Table 1. Clinical data of study population at delivery (healthy pregnant women and women with 
preeclampsia participating in the study). Continuous variables are presented as mean±SE or median 
(range) and categorical variables as n (%) as appropriate.  
 
Table 2. Summary of results from the tissue microarray immunohistochemistry analysis according to 
subcellular localization of laeverin protein between (A) Normal and preeclamptic placentas and (B) 
early- and late-onset preeclampsia. Note that 2 of 41 normal and 3 of 36 preeclamptic placentas 
could not be scored because of weak or no-expression of laeverin due to technical issues. 
 
Figure 1. Tissue microarray (TMA) protocol. The tissue area of interest was identified on the 
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(pink). The microarray was assembled in a paraffin recipient block precut with a tissue-arrayer (blue) 
with a slightly bigger diameter. After inserting all different patient cores in the recipient block, the 
paraffin block was heated to make an uniform TMA-block. Immunohistochemistry (IHC) or 
immunofluorescence (IF) were then performed on different slides from the same TMA-block. Slides 
were analyzed in microscopes, databases were made and SPSS-statistics done.  
 
Figure 2. Tissue microarray immunohistochemistry of healthy- (A-C) and preeclamptic placentas (D-
E) labelled with laeverin antibody (brown). A) Healthy placenta showing laeverin staining in 
syncytiotrophoblast membranes of chorion villi. B) Healthy placenta showing laeverin membrane 
staining in syncytiotrophoblasts and in extravillous trophoblasts. C) Healthy placenta showing 
membrane- and cytoplasma staining of syncytio- and cytrotrophoblast cells in chorion villi. D) 
Placenta from preeclamptic patient showing cytoplasmic staining of  syncytio- and cytrotrophoblast 
cells in chorion villi. In fetal capillaries (FC) red blood cells are depicted. Several syncytial knots are 
seen in this patient, one of these is highlighted in the right column labelled SK. E) Placenta from 
preeclamptic patient showing cytoplasmic staining of  syncytio- and cytrotrophoblast cells in chorion 
villi. In fetal capillaries (FC) red blood cells are depicted. F) Negative control (liver tissue) stained with 
laeverin shows no membrane nor cytoplasmic staining, but some areas of pigment staining. In the 
left column 10x magnification of tissue microarray cores are shown. Areas further magnified (40x 
magnification) are depicted in the right column. EVT=extravillous trophoblasts, FC=fetal capillaries, 
SK=syncytial knot and ST=stroma. Nuclei are counterstained (blue). Scale bars are 200 μm (low 
resolution pictures) or 50 μm (high resolution pictures). 
 
Figure 3. Tissue microarray immunofluorescence of healthy- (A) and preeclamptic (B) placentas 
labelled with laeverin antibody (red) and cytokeratin 7 (CK7)(green). A) Laeverin (red) is expressed in 
the plasma membrane of syncytiotrophoblast cells in healthy placenta (this is the same placenta as 
in Figure 2A). CK7 (green) is localized in the cytoplasm of trophoblastic cells. B) Preeclamptic 
placenta shows partly co-localized laeverin and cytokeratin in the cytoplasm. Fetal capillaries (FC) 
inside chorionic villi containing red blood cells (pink and blue) are shown. C) Liver cells stained with 
laeverin and CK7 showed no staining. Nuclei were counterstained with DAPI II (blue). FC=fetal 
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Table 1. Clinical data of study population at delivery (healthy pregnant women and women with 
preeclampsia participating in the study). Continuous variables are presented as mean±SE or median 





P value  
Maternal age, 
median (range), years 
31 (17-40) 31 (21-43) 0.741 
Body mass index 
before delivery, (kg/m2) 
30.2±0.71 29.8±0.64 0.846 
Primipara, n (%) 19 (46) 20 (56) 0.420 
Mean arterial pressure,
mmHg 
88.8±2.1 123.5±2.1 p<0.0001 
Uterine artery pulsatility index  
(mean of the left and right side) 
0.74±0.0 1.32±0.23 p<0.0001 
Middle cerebral artery pulsatility index 1.30±0.06 1.37±0.08 0.433 
Umbilical artery   
pulsatility index 
0.77±0.03 1.35±0.13 p<0.0001 
Gestational age at delivery,  
median (range), weeks 
39 (35-42) 35 (26-42) p<0.0001 
Cesarean section (emergency/elective), 
n (%) 
21 (5/16) (51) 28 (28/0)(78) 0.016 
Neonatal birth weight, g 3621±90 2067±161 p<0.0001 
Placental weight, g 679±31 253±43 0.001 
5 min APGAR score 
median (range) 
10 (7-10) 9 (0-10) 0.006 
Arterial cord blood pH 7.27±0.01 7.26±0.02 0.376 
Arterial cord blood Base Excess -3.23±0.56 -2.87±0.72 0.691 
Venous cord blood pH 7.34±0.01 7.28±0.02 0.011 
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Table 2. Summary of results from the TMA immunohistochemistry analysis according to 
subcellular localization of laeverin protein between (A) Normal and preeclamptic placentas and (B) 
early- and late-onset preeclampsia. Note that 2 of 41 normal and 3 of 36 preeclamptic placentas 







Plasma membrane 21 (54%) 21 (64%) 0.726
Plasma membrane 
and cytoplasma 
16 (41%) 9 (27%) 0.522





 Early-onset  
(n=15) 
Late-onset (n=18) P value
Plasma 
membrane 




3 (9.1%) 6 (18.2%) 0.408
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